Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
EPIGIST: An observational real-life study on patients with metastatic gastrointestinal stromal tumors receiving imatinib.
Bouché O, Cesne AL, Rios M, Chaigneau L, Italiano A, Duffaud F, Lecomte T, Arsène D, Manfredi S, Aparicio T, Remy S, Isambert N, Collard O, Priou F, Bertucci F, Sambuc R, Bisot-Locard S, Bourges O, Chabaud S, Blay JY. Bouché O, et al. Among authors: bisot locard s. PLoS One. 2018 Sep 18;13(9):e0204117. doi: 10.1371/journal.pone.0204117. eCollection 2018. PLoS One. 2018. PMID: 30226855 Free PMC article.
Observational Study in a Real-World Setting of Targeted Therapy in the Systemic Treatment of Progressive Unresectable or Metastatic Well-Differentiated Pancreatic Neuroendocrine Tumors (pNETs) in France: OPALINE Study.
Smith D, Lepage C, Vicaut E, Dominguez S, Coriat R, Dubreuil O, Lecomte T, Baudin E, Venat Bouvet L, Samalin E, Santos A, Borie O, Bisot-Locard S, Goichot B, Lombard-Bohas C. Smith D, et al. Among authors: bisot locard s. Adv Ther. 2022 Jun;39(6):2731-2748. doi: 10.1007/s12325-022-02103-7. Epub 2022 Apr 13. Adv Ther. 2022. PMID: 35419649 Free PMC article.
Evaluation of Nurses' and Patients' Overall Satisfaction with New and Previous Formulations of Octreotide Long-acting Release (Sandostatin LAR®): A French Observational Study.
Delemer B, Nguyen-Tan-Hon T, Coriat R, Smith D, Schillo F, Raingeard I, Sobhani I, Etienne PL, Decoudier B, Bisot-Locard S, Santos A, Raverot G, Cadiot G. Delemer B, et al. Among authors: bisot locard s. Adv Ther. 2020 Sep;37(9):3901-3915. doi: 10.1007/s12325-020-01429-4. Epub 2020 Jul 18. Adv Ther. 2020. PMID: 32683667
Predictive Factors of Somatostatin Receptor Ligand Response in Acromegaly-A Prospective Study.
Ilie MD, Tabarin A, Vasiljevic A, Bonneville JF, Moreau-Grangé L, Schillo F, Delemer B, Barlier A, Figarella-Branger D, Bisot-Locard S, Santos A, Chanson P, Raverot G. Ilie MD, et al. Among authors: bisot locard s. J Clin Endocrinol Metab. 2022 Nov 23;107(11):2982-2991. doi: 10.1210/clinem/dgac512. J Clin Endocrinol Metab. 2022. PMID: 36136828
Patients lost to follow-up in acromegaly: results of the ACROSPECT study.
Delemer B, Chanson P, Foubert L, Borson-Chazot F, Chabre O, Tabarin A, Weryha G, Cortet-Rudelli C, Raingeard I, Reznik Y, Reines C, Bisot-Locard S, Castinetti F. Delemer B, et al. Among authors: bisot locard s. Eur J Endocrinol. 2014 Apr 19;170(5):791-7. doi: 10.1530/EJE-13-0924. Print 2014 May. Eur J Endocrinol. 2014. PMID: 24591552
Octreotide (long-acting release formulation) treatment in patients with graves' orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study.
Wémeau JL, Caron P, Beckers A, Rohmer V, Orgiazzi J, Borson-Chazot F, Nocaudie M, Perimenis P, Bisot-Locard S, Bourdeix I, Dejager S. Wémeau JL, et al. J Clin Endocrinol Metab. 2005 Feb;90(2):841-8. doi: 10.1210/jc.2004-1334. Epub 2004 Nov 23. J Clin Endocrinol Metab. 2005. PMID: 15562016 Free article. Clinical Trial.
17 results